6-Year checkup: does the EV71 vaccine still shield kids?
NCT ID NCT07568522
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows up on 220 children who received the EV71 vaccine (Envacgen®) or a placebo about 6 years ago. Researchers will measure antibody levels in the blood to see if protection against enterovirus 71, which causes hand-foot-mouth disease, has lasted. The goal is to understand the vaccine's long-term effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Inactivated EV71 enterovirus vaccine (Envacgen®) with adjuvant AlPO4
- What this could lead to
- If successful, this study could show that the EV71 vaccine provides long-lasting protection against hand-foot-mouth disease caused by enterovirus 71.
- What could go wrong
- This is an observational follow-up, not a new treatment test. It only measures antibody levels, not actual disease prevention, and results may not apply to all populations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENTEROVIRUS 71 HUMAN are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Chang Gung Medical Hospital Linkou
Taoyuan, Taiwan
-
Mackay Memorial Hospital, HsincChu
Hsinchu, Taiwan
-
Mackay Memorial Hospital, Taipei
Taipei, Taiwan
-
National Taiwan University Hospital
Taipei, Taiwan